Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib

Haematologica. 2019 May;104(5):e218-e221. doi: 10.3324/haematol.2018.215103. Epub 2019 Feb 28.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase / genetics
  • Anaplastic Lymphoma Kinase / metabolism*
  • Antineoplastic Agents / therapeutic use*
  • Crizotinib / therapeutic use*
  • Humans
  • Infant
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / genetics
  • Lymphoma, Large-Cell, Anaplastic / metabolism
  • Lymphoma, Large-Cell, Anaplastic / pathology
  • Male
  • Oncogene Proteins, Fusion*
  • Poly(A)-Binding Protein I / genetics
  • Poly(A)-Binding Protein I / metabolism*
  • Prognosis

Substances

  • Antineoplastic Agents
  • Oncogene Proteins, Fusion
  • Poly(A)-Binding Protein I
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase